Home · Pharmacies · Red Rock Pharmacy
Compounding pharmacy profileRed Rock Pharmacy: what the records show
As of October 14, 2026, Red Rock Pharmacy (CD Pharmacy, LLC dba Red Rock Pharmacy, Springville, Utah) is a 503A compounding pharmacy that lists semaglutide, tirzepatide and combination GLP-1 injections. The FDA issued it a Form 483 with ten observations on July 31, 2026, naming semaglutide-glycine and tirzepatide-methylcobalamin injections among the products reviewed.
Red Rock at a glance
| Legal name | CD Pharmacy, LLC dba Red Rock Pharmacy |
|---|---|
| Location | 863 W 450 S, Ste 101, Springville, UT; also a St. George, UT location |
| Type | 503A compounding pharmacy |
| On FDA 503B list | No |
| Accreditations it claims | None found |
| States | Its pages conflict: "licensed in 49 states"; the Springville contact page says it serves all states except California, Nevada and Arkansas |
| GLP-1 products it lists | Semaglutide, tirzepatide, tirzepatide/semaglutide combination, liraglutide; FDA 483 names semaglutide-glycine and tirzepatide-methylcobalamin |
| FDA actions 2026 | Form 483 issued July 31, 2026 (inspection July 21–31, 2026), 10 observations |
Accreditation claims are the pharmacy's own; we could not check them against LegitScript's or ACHC's lookups, which were not publicly reachable. Every other row cites a source listed below.
What the July 2026 FDA inspection found
The FDA inspected Red Rock's Springville facility from July 21 to July 31, 2026 and issued a Form 483 with ten observations. They include that the pharmacy "released drug product in which the strength differs from, or its purity or quality falls below" its stated quality, and that "media fills do not simulate the most challenging production conditions." A Form 483 lists an investigator's observations; it is not a final agency finding, and a warning letter may or may not follow. We found no warning letter as of October 14, 2026.
Additive formulations
The products named in the 483 include semaglutide-glycine (5 mg–2 mg/mL) and tirzepatide-methylcobalamin (17 mg–100 mcg/mL). The FDA said in April 2026 that semaglutide combined with another ingredient such as vitamin B12 may still be "essentially a copy" of an approved drug, and its September 2026 Empower letter applied the same reasoning to tirzepatide/niacinamide. Read what the B12, glycine and niacinamide add-ins actually do.
Who dispenses through Red Rock
When we read NexLife's microdose pages on September 17, 2026, their disclaimer listed Red Rock among five 503A pharmacies (with Absolute, Hallandale, Empower and Strive); NexLife's standard tirzepatide plan page names three others (Absolute, Premium Compounding and Boudreaux's New Drug Store). Correction: earlier editions of this page placed Red Rock in South Jordan, Utah, gave a 2009 founding date and described PCAB accreditation; none of those statements is supported by the records we checked on October 14, 2026.
How to verify this pharmacy yourself
Read the dispensing pharmacy's name on your vial label, then check its license with your state board of pharmacy, search the FDA outsourcing facility list if it claims 503B status, and scan the FDA's compounding inspections and actions page. Our 503A vs 503B guide explains the difference.
What the two quoted observations mean
Two of the ten observations in Red Rock's July 31, 2026 Form 483 bear directly on product quality:
- "Released drug product in which the strength differs from, or its purity or quality falls below" its stated quality. This concerns potency and purity. A batch may have contained more or less drug than its label states, or failed a quality measure, and was still released.
- "Media fills do not simulate the most challenging production conditions." A media fill runs a nutrient broth through the sterile process in place of the drug to show the process does not let microbes in. If the test skips the hardest real-world conditions, it may not show that every batch is sterile. The FDA cited the same type of gap at Hallandale in 2020 and at Empower in September 2026.
The FDA's compounding actions page (current as of October 22, 2026) lists the 483 under "CD Pharmacy LLC (dba Red Rock Pharmacy), Springville, UT" as a 503A facility and shows no warning letter. The FDA's separate 2026 pharmacy inspection records page, current as of August 19, 2026, did not yet include it.
How much tirzepatide and B12 is in each dose?
The 483 names a tirzepatide-methylcobalamin injection at 17 mg tirzepatide and 100 mcg methylcobalamin (a form of vitamin B12) per mL. At that concentration, the standard Zepbound-label doses work out as follows. Volumes use a U-100 syringe, where 1 unit equals 0.01 mL.
| Weekly tirzepatide dose | Volume | Syringe units (U-100) | Methylcobalamin in that dose |
|---|---|---|---|
| 2.5 mg | 0.15 mL | about 15 | about 15 mcg |
| 5 mg | 0.29 mL | about 29 | about 29 mcg |
| 7.5 mg | 0.44 mL | about 44 | about 44 mcg |
| 10 mg | 0.59 mL | about 59 | about 59 mcg |
| 12.5 mg | 0.74 mL | about 74 | about 74 mcg |
| 15 mg | 0.88 mL | about 88 | about 88 mcg |
This table applies only to a 17 mg/mL vial. If your label shows a different concentration, the units change. Ask the pharmacy or prescriber to confirm units in writing.
What is known about the B12 add-in:
- Eli Lilly said in a March 12, 2026 open letter that its testing found an impurity formed when tirzepatide reacts with B12. This is Lilly's claim. We found no FDA statement on that impurity.
- The FDA's January 16, 2026 warning letter to Boothwyn, a different firm, said a tirzepatide/glycine/methylcobalamin product failed sterility testing.
- A 2026 Annals of Pharmacotherapy review of 33 compounded GLP-1 products found "little justification for adding nutrients."
See our additives explainer.
What to do if your vial says Red Rock
- Check the label for the pharmacy name, the concentration (for example 17 mg/mL) and any added ingredient.
- Ask your prescriber why an additive was chosen and confirm the dose in mL and syringe units.
- Check that Red Rock serves your state. One of its pages says it is "licensed in 49 states," while the Springville contact page excludes California, Nevada and Arkansas.
- Report a problem to the pharmacy, your prescriber and the FDA's MedWatch program. The FDA said as of May 31, 2026 it had received more than 730 adverse-event reports linked to compounded tirzepatide.
Compounded tirzepatide is not FDA-approved, whichever pharmacy makes it.
A Form 483 does not by itself mean a recall. If the FDA or the pharmacy recalls a lot, the notice lists lot numbers, so keep the label of every vial you use until it is finished.
More questions
Has the FDA sent Red Rock Pharmacy a warning letter?
We found none. The FDA's compounding actions page, current as of October 22, 2026, lists only the July 31, 2026 Form 483 for Red Rock.
How much B12 is in a dose of Red Rock's tirzepatide-methylcobalamin?
At the 17 mg/100 mcg per mL strength named in the 483, a 2.5 mg dose contains about 15 mcg of methylcobalamin and a 15 mg dose about 88 mcg. Check the concentration on your own label.
Is Red Rock Pharmacy registered as a 503B outsourcing facility?
No. It does not appear on the FDA's outsourcing facility list updated October 29, 2026, and the FDA classifies it as 503A.
Further sources
- FDA: Compounding: Inspections, Recalls, and other Actions (content current as of October 22, 2026)
- FDA: 2026 pharmacy inspections and related records (content current as of August 19, 2026)
- FDA: Registered Outsourcing Facilities (list updated October 29, 2026)
- Eli Lilly: Zepbound (tirzepatide) prescribing information
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026)
Frequently asked questions
Where is Red Rock Pharmacy located?
Springville, Utah (863 W 450 S), with a second location in St. George, Utah.
Is Red Rock Pharmacy 503A or 503B?
503A. The FDA lists it as a 503A facility and it is not on the registered outsourcing facility list.
Did the FDA inspect Red Rock Pharmacy?
Yes. An inspection ended July 31, 2026 with a Form 483 listing ten observations.
Sources
Other pharmacy profiles: Empower Pharmacy · Hallandale Pharmacy · MediVera Compounding Pharmacy · Strive Pharmacy · Absolute Pharmacy · all pharmacies
Informational only. A pharmacy profile is not an endorsement. Compounded drugs are not FDA-approved.